Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study.

White KA, Luo L, Thompson TA, Torres S, Hu CA, Thomas NE, Lilyquist J, Anton-Culver H, Gruber SB, From L, Busam KJ, Orlow I, Kanetsky PA, Marrett LD, Gallagher RP, Sacchetto L, Rosso S, Dwyer T, Cust AE, Begg CB, Berwick M; GEM Study Group.

Cancer Med. 2016 Nov;5(11):3336-3345. doi: 10.1002/cam4.929. Epub 2016 Oct 17.

2.

The bimodal P300 oddball component is decreased in patients with an adjustment disorder: An event-related potentials study.

Kajosch H, Gallhofer B, Corten P, From L, Verbanck P, Campanella S.

Clin Neurophysiol. 2016 Oct;127(10):3209-16. doi: 10.1016/j.clinph.2016.07.009. Epub 2016 Jul 27.

PMID:
27521621
3.

Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.

Taylor NJ, Thomas NE, Anton-Culver H, Armstrong BK, Begg CB, Busam KJ, Cust AE, Dwyer T, From L, Gallagher RP, Gruber SB, Nishri DE, Orlow I, Rosso S, Venn AJ, Zanetti R, Berwick M, Kanetsky PA; GEM Study Group.

Int J Cancer. 2016 Sep 15;139(6):1217-22. doi: 10.1002/ijc.30157. Epub 2016 May 30.

4.

Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways.

Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

J Natl Cancer Inst. 2016 Feb 8;108(7). pii: djw004. doi: 10.1093/jnci/djw004. Print 2016 Jul.

5.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

6.

Inherited genetic variants associated with occurrence of multiple primary melanoma.

Gibbs DC, Orlow I, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):992-7. doi: 10.1158/1055-9965.EPI-14-1426. Epub 2015 Apr 2.

7.

Inherited variation at MC1R and histological characteristics of primary melanoma.

Taylor NJ, Busam KJ, From L, Groben PA, Anton-Culver H, Cust AE, Begg CB, Dwyer T, Gallagher RP, Gruber SB, Orlow I, Rosso S, Thomas NE, Zanetti R, Rebbeck TR, Berwick M, Kanetsky PA.

PLoS One. 2015 Mar 19;10(3):e0119920. doi: 10.1371/journal.pone.0119920. eCollection 2015.

8.

Inherited variation at MC1R and ASIP and association with melanoma-specific survival.

Taylor NJ, Reiner AS, Begg CB, Cust AE, Busam KJ, Anton-Culver H, Dwyer T, From L, Gallagher RP, Gruber SB, Rosso S, White KA, Zanetti R, Orlow I, Thomas NE, Rebbeck TR, Berwick M, Kanetsky PA; GEM Study Group.

Int J Cancer. 2015 Jun 1;136(11):2659-67. doi: 10.1002/ijc.29317. Epub 2014 Nov 26.

9.

Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Thomas NE, Kricker A, Waxweiler WT, Dillon PM, Busman KJ, From L, Groben PA, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Orlow I, Paine S, Ollila DW, Reiner AS, Luo L, Hao H, Frank JS, Begg CB, Berwick M; Genes, Environment, and Melanoma (GEM) Study Group.

JAMA Dermatol. 2014 Dec;150(12):1306-314.

10.

Sun exposure and melanoma survival: a GEM study.

Berwick M, Reiner AS, Paine S, Armstrong BK, Kricker A, Goumas C, Cust AE, Thomas NE, Groben PA, From L, Busam K, Orlow I, Marrett LD, Gallagher RP, Gruber SB, Anton-Culver H, Rosso S, Zanetti R, Kanetsky PA, Dwyer T, Venn A, Lee-Taylor J, Begg CB; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2145-52. doi: 10.1158/1055-9965.EPI-14-0431. Epub 2014 Jul 28.

11.

MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors.

Berwick M, MacArthur J, Orlow I, Kanetsky P, Begg CB, Luo L, Reiner A, Sharma A, Armstrong BK, Kricker A, Cust AE, Marrett LD, Gruber SB, Anton-Culver H, Zanetti R, Rosso S, Gallagher RP, Dwyer T, Venn A, Busam K, From L, White K, Thomas NE; GEM Study Group.

Pigment Cell Melanoma Res. 2014 May;27(3):485-8. doi: 10.1111/pcmr.12215. Epub 2014 Jan 30.

12.

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Groben PA, Hao H, Orlow I, Reiner AS, Luo L, Paine S, Ollila DW, Wilcox H, Begg CB, Berwick M.

J Clin Oncol. 2013 Nov 20;31(33):4252-9. doi: 10.1200/JCO.2013.51.3002. Epub 2013 Oct 14.

13.

Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study.

Kricker A, Armstrong BK, Goumas C, Thomas NE, From L, Busam K, Kanetsky PA, Gallagher RP, Marrett LD, Groben PA, Gruber SB, Anton-Culver H, Rosso S, Dwyer T, Berwick M; GEM Study Group.

JAMA Dermatol. 2013 Aug;149(8):921-7. doi: 10.1001/jamadermatol.2013.4581.

14.

Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.

Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB; GEM Study Investigators.

J Natl Cancer Inst. 2012 Jun 20;104(12):953-6. doi: 10.1093/jnci/djs221. Epub 2012 Apr 24.

15.

Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Murali R, Goumas C, Kricker A, From L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Orlow I, Rosso S, Thomas NE, Berwick M, Scolyer RA, Armstrong BK; GEM Study Group.

Ann Surg Oncol. 2012 Mar;19(3):1024-33. doi: 10.1245/s10434-011-2058-8. Epub 2011 Sep 13. Erratum in: Ann Surg Oncol. 2013 Dec; 30 Suppl 3:S747-8.

16.

Inter-observer concordance for the recognition of angiotropism in human melanoma.

Barnhill RL, Busam KJ, From L, Bagot M, Lugassy C, Berwick M.

Pigment Cell Melanoma Res. 2011 Jun;24(3):582-3. doi: 10.1111/j.1755-148X.2011.00854.x. Epub 2011 Apr 28. No abstract available.

PMID:
21466662
17.

Vitamin D receptor polymorphisms in patients with cutaneous melanoma.

Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Thomas NE, Gruber SB, Anton-Culver H, Rosso S, Gallagher RP, Dwyer T, Kanetsky PA, Busam K, From L, Begg CB, Berwick M; GEM Study Group.

Int J Cancer. 2012 Jan 15;130(2):405-18. doi: 10.1002/ijc.26023. Epub 2011 Apr 25.

18.

Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis.

Thomas NE, Kricker A, From L, Busam K, Millikan RC, Ritchey ME, Armstrong BK, Lee-Taylor J, Marrett LD, Anton-Culver H, Zanetti R, Rosso S, Gallagher RP, Dwyer T, Goumas C, Kanetsky PA, Begg CB, Orlow I, Wilcox H, Paine S, Berwick M; Genes, Environment, and Melanoma Study Group.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2932-41. doi: 10.1158/1055-9965.EPI-10-0686. Epub 2010 Aug 27.

19.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
20.
21.

CDKN2A germline mutations in individuals with cutaneous malignant melanoma.

Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Wilcox H, Busam K, From L, Berwick M; GEM Study Group.

J Invest Dermatol. 2007 May;127(5):1234-43. Epub 2007 Jan 11.

22.

Ambient UV, personal sun exposure and risk of multiple primary melanomas.

Kricker A, Armstrong BK, Goumas C, Litchfield M, Begg CB, Hummer AJ, Marrett LD, Theis B, Millikan RC, Thomas N, Culver HA, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From L, Mujumdar U, Zanetti R, Berwick M; GEM Study Group.

Cancer Causes Control. 2007 Apr;18(3):295-304. Epub 2007 Jan 6.

23.

Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma.

Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Busam K, From L, Mujumdar U, Wilcox H, Begg CB, Berwick M.

Cancer Res. 2006 Sep 15;66(18):9330-7.

24.

The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.

Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H, Begg CB; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1520-5.

25.

A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma.

Begg CB, Hummer AJ, Mujumdar U, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Busam K, From L, Berwick M; GEM Study Group.

Int J Epidemiol. 2006 Jun;35(3):756-64. Epub 2006 Mar 23.

26.

Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study.

Millikan RC, Hummer A, Begg C, Player J, de Cotret AR, Winkel S, Mohrenweiser H, Thomas N, Armstrong B, Kricker A, Marrett LD, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Busam K, From L, Mujumdar U, Berwick M.

Carcinogenesis. 2006 Mar;27(3):610-8. Epub 2005 Oct 29.

27.

Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.

Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; Genes Environment and Melanoma Study Group.

J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15.

28.

Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma.

Purdue MP, From L, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD; Genes, Environment, and Melanoma Study Group.

Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2015-22.

29.

Characterizing anxiety in melanoma patients.

Missiha SB, Solish N, From L.

J Cutan Med Surg. 2003 Nov-Dec;7(6):443-8.

PMID:
15926214
30.

Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma.

Purdue MP, From L, Kahn HJ, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD.

Int J Cancer. 2005 Nov 10;117(3):486-93.

31.
32.

The Canadian Dermatology Workforce Survey: implications for the future of Canadian dermatology--who will be your skin expert?

Maguiness S, Searles GE, From L, Swiggum S.

J Cutan Med Surg. 2004 May-Jun;8(3):141-7. Epub 2004 Sep 9.

PMID:
15578128
33.

Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?

Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, Elenitsas R, From L, Guitart J, Horenstein MG, Ming ME, Piepkorn MW, Rabkin MS, Reed JA, Selim MA, Trotter MJ, Johnson MM, Shea CR.

Am J Clin Pathol. 2003 Aug;120(2):203-8.

PMID:
12931550
34.

Barriers to sun safety in a Canadian outpatient population.

Boggild AK, From L.

J Cutan Med Surg. 2003 Jul-Aug;7(4):292-9. Epub 2003 Jul 28.

PMID:
12879334
35.

The Ontario sun safety working group.

Marrett LD, Broadhurst D, Charron S, Fraser L, From L, Hunter W, Payne P, Yarema ML, Rosen C.

Chronic Dis Can. 2003 Winter;24(1):27-31. No abstract available.

PMID:
12757633
36.

Use of focus group methodology in the development of an Ontario farmers' sun safety survey.

Ing SY, Ashbury FD, Marrett LD, From L, Perry KV.

Chronic Dis Can. 2002 Spring;23(2):65-70.

PMID:
12095457
37.
38.

Malignant melanoma in a patient with oculocutaneous albinism.

Streutker CJ, McCready D, Jimbow K, From L.

J Cutan Med Surg. 2000 Jul;4(3):149-52.

PMID:
11003720
39.

Lack of germline CDK6 mutations in familial melanoma.

Shennan MG, Badin AC, Walsh S, Summers A, From L, McKenzie M, Goldstein AM, Tucker MA, Hogg D, Lassam N.

Oncogene. 2000 Mar 30;19(14):1849-52.

40.

Detection of artificial changes in mole size by skin self-examination.

Muhn CY, From L, Glied M.

J Am Acad Dermatol. 2000 May;42(5 Pt 1):754-9.

PMID:
10775850
41.

Eyelid resurfacing.

Harris DM, Fried D, Reinisch L, Bell T, Schachter D, From L, Burkart J.

Lasers Surg Med. 1999;25(2):107-22. Erratum in: Lasers Surg Med 2000;26(4):415.

PMID:
10455216
42.

Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome.

Barnhill RL, Argenyi ZB, From L, Glass LF, Maize JC, Mihm MC Jr, Rabkin MS, Ronan SG, White WL, Piepkorn M.

Hum Pathol. 1999 May;30(5):513-20.

PMID:
10333219
43.

Sun safety knowledge and behaviour: new data on which to build.

From L.

Cancer Prev Control. 1998 Jun;2(3):103-4. No abstract available.

PMID:
10093618
44.

Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma.

Hogg D, Brill H, Liu L, Monzon J, Summers A, From L, Lassam NJ.

J Cutan Med Surg. 1998 Jan;2(3):172-9. Review.

PMID:
9479083
45.

CDKN2A mutations in multiple primary melanomas.

Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ.

N Engl J Med. 1998 Mar 26;338(13):879-87.

46.

Family physicians' knowledge of malignant melanoma.

Stephenson A, From L, Cohen A, Tipping J.

J Am Acad Dermatol. 1997 Dec;37(6):953-7.

PMID:
9418763
47.

Ultrasound backscatter microscope analysis of mouse melanoma progression.

Turnbull DH, Ramsay JA, Shivji GS, Bloomfield TS, From L, Sauder DN, Foster FS.

Ultrasound Med Biol. 1996;22(7):845-53.

PMID:
8923704
48.

MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.

Ramsay JA, From L, Iscoe NA, Kahn HJ.

J Invest Dermatol. 1995 Jul;105(1):22-6.

49.

Does high-frequency (40-60 MHz) ultrasound imaging play a role in the clinical management of cutaneous melanoma?

Semple JL, Gupta AK, From L, Harasiewicz KA, Sauder DN, Foster FS, Turnbull DH.

Ann Plast Surg. 1995 Jun;34(6):599-605; discussion 606.

PMID:
7661536
50.

bcl-2 protein expression in melanocytic neoplasms of the skin.

Ramsay JA, From L, Kahn HJ.

Mod Pathol. 1995 Feb;8(2):150-4.

PMID:
7777475

Supplemental Content

Support Center